Abstract
Post-translational protein modifications can play a significant role in immune cell signaling. Recently, we showed that inhibition of transmethylation curtails experimental autoimmune encephalomyelitis, notably by reducing T cell receptor (TCR)-induced activation of CD4+ T cells. Here, we demonstrate that transmethylation inhibition by a reversible S-adenosyl-l-homocysteine hydrolase inhibitor (DZ2002) led to immunosuppression by reducing TLR-, B cell receptor (BCR)- and TCR-induced activation of immune cells, most likely by blocking NF-κB activity. Moreover, prophylactic treatment with DZ2002 prevented lupus-like disease from developing in both BXSB and MRL-Faslpr mouse models. DZ2002 treatment initiated during active disease significantly improved outcomes in both in vivo models, suggesting methylation inhibition as a novel approach for the treatment of autoimmune/inflammatory diseases.
Original language | English |
---|---|
Pages (from-to) | 133-143 |
Number of pages | 11 |
Journal | Clinical Immunology |
Volume | 147 |
Issue number | 2 |
DOIs | |
State | Published - May 2013 |
Externally published | Yes |
Keywords
- Lymphocytes
- S-adenosyl-l-homocysteine hydrolase
- Systemic lupus erythematosus
- Toll-like receptors
- Transmethylation
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Immunology